Authors
Latest:
Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancerAlexander Drilon, MD presents data from the 2021 American Society of Clinical Oncology annual meeting from trials in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer treated with larotrectinib.
Latest:
Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLCAlexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.
Latest:
Dr. Perl on CAR T Cells in Pediatric LeukemiaAlexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.
Latest:
Dr. Perl on Genetic Testing and Targeted Therapies in AMLAlexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.
Latest:
Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCCAlexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.
Latest:
Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCCAlexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.
Latest:
Fox Chase Investigates Screening Methods to Avoid Unnecessary Radical CystectomyCurrently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.
Latest:
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring CystectomyAlexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Latest:
Dr. Lazarides on Research Regarding Margin Assessment in SarcomaAlexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.
Latest:
Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple MyelomaAlexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.
Latest:
Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced MelanomaAlexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.
Latest:
Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced MelanomaAlexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.
Latest:
Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLCAlexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).
Latest:
Dr. Ring on Molecular Profiling of CTCs in Advanced Breast CancerAlexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.
Latest:
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA StudyA secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.
Latest:
Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLCAlexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.
Latest:
Dr Drakaki on Nivolumab/Ipilimumab in Advanced RCC With Sarcomatoid DifferentiationAlexandra Drakaki, MD, PhD, discusses nivolumab plus ipilimumab in the treatment of renal cell carcinoma with sarcomatoid differentiation.
Latest:
Dr. Taylor on the Future of Treatments for Endometrial CancerAlexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer.
Latest:
Targeting Cell Cycle Progression: CDK4/6 Inhibition in Breast CancerCyclin-dependent kinase (CDK) 4/6 inhibitors are novel agents that have shown promising results in the treatment of breast cancer.
Latest:
Dr. Phan Discusses Challenges With Treating pNETsAlexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).
Latest:
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MDDrs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
Latest:
The Future of Melanoma TreatmentDrugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.
